Improvements in Scaling and Sequencing for Allogeneic Cell Therapies for Oncology

During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies. How are we going to keep the costs under control? How are we going to be able to supply the clinic? What is the angle that your company works from? What is the secret sauce, if you will, and how are you going to take advantage of it? Is that something that you want to do through a contract organization? Is that something that you want to build internally? Tune in to hear their discussion that addresses these important questions.